3. Adrenergic Drugs
Overview and General Concepts of Adrenergic Drugs
Definitions and Terminology:
Sympathomimetics (Adrenergic Stimulants): Agonists and substances that produce physiological effects similar to those resulting from the stimulation of sympathetic nervous activity.
Sympatholytics (Antiadrenergics / Adrenergic-Blocking Agents): Antagonists and substances that decrease or inhibit sympathetic nervous activity.
Physiological Responses to Sympathetic ("Fight or Flight") Stimulation:
Acceleration of heart rate and lung action.
Relaxation of the urinary bladder.
Dilation of the pupil ().
Constriction of smooth muscle in blood vessels.
Inhibition of erection.
Decreased secretion from exocrine glands (including salivary and tear glands).
Opening-up (dilation) of respiratory tract airways.
Mobilization of energy stores (particularly fat and glucose) for muscular action.
Endogenous Catecholamines and Physicochemical Properties
Chemical Substructures:
Catechol: ( ring system).
: Benzene ring attached to a two-carbon chain ( and carbons) terminating in an amine group.
Ethylamine: Two-carbon chain attached to an amine ().
Catecholamine: Composite structure consisting of a catechol ring linked to an ethylamine side chain.
Endogenous Catecholamines:
Dopamine (DA): Catechol ring with an unsubstituted ethylamine chain.
Norepinephrine (NE / Noradrenaline): Catechol ring with a group and a primary amine.
Epinephrine (E / Adrenaline): Catechol ring with a group and an group ().
General Physicochemical & Pharmacokinetic Properties:
All endogenous catecholamines are polar molecules.
Extensively metabolized by both Monoamine Oxidase () and Catechol-O-methyltransferase ().
Orally inactive due to rapid enzymatic degradation.
Possess a very short duration of action ().
Biosynthesis and Neuronal Handling of Catecholamines
Biosynthetic Pathway:
is transported into vesicles via Vesicular Monoamine Transporter () driven by an gradient.
(utilizing as the methyl donor).
Neuronal Terminal Events & Pharmacological Interventions:
enters the presynaptic terminal via a transporter.
Metyrosine: Inhibits , blocking the initial rate-limiting step of biosynthesis.
Reserpine: Inhibits , preventing vesicle storage and causing catecholamine depletion.
Calcium Channels: Action potentials trigger influx through voltage-gated calcium channels, promoting vesicle fusion.
Exocytosis: Release of , , and peptides () from vesicles into the synaptic cleft.
Exocytotic release is inhibited by Bretylium and Guanethidine.
Receptor Binding: Released acts on presynaptic autoreceptors/heteroreceptors and postsynaptic adrenoceptors.
Reuptake via NET: clears from the synapse back into the axon terminal.
is inhibited by Cocaine and Tricyclic Antidepressants.
Metabolism of Catecholamines by MAO and COMT
Monoamine Oxidase (MAO):
Localization: Mitochondrial enzyme.
Reaction: Oxidizes primary () or secondary () amines into aldehydes ().
() or () .
Catechol-O-Methyltransferase (COMT):
Reaction: Adds a methyl group to the () position of catechol substrates.
() ().
() ().
Downstream Enzymatic Transformations:
(Oxidation from aldehyde to carboxylic acid).
(Reduction from aldehyde to alcohol).
or [also known as Vanillylmandelic Acid (VMA)].
or .
Oxidation Levels Summary:
Alcohol () Aldehyde () Carboxylic Acid ().
Dehydrogenase enzymes catalyze oxidation; Reductase enzymes catalyze reduction.
Clinical Diagnostic Marker:
Vanillylmandelic Acid (VMA): Major final excretion end product of and metabolism.
Urinary levels are significantly elevated in patients with catecholamine-secreting tumors, such as the adrenal gland tumor pheochromocytoma.
Structure-Activity Relationships (SAR) of Phenylethylamine Agonists
Minimal Structural Requirements for Direct Activity:
core.
Catechol ring (or suitable aromatic modification).
at the .
Stereochemistry at the :
The is substantially more active than the .
establishes a three-point receptor binding fit (hydrogen bonding via , ionic bonding via protonated amine, aromatic interaction).
lacks proper alignment for the hydrogen-bonding interaction.
Aromatic Ring Substitution SAR:
(Catechol): Confers both and agonist activity. Substrate for , resulting in poor oral bioavailability and short . Highly hydrophilic, leading to poor penetration.
(Resorcinol ring, e.g., Metaproterenol): Increases selectivity. Resistant to metabolism, leading to increased absorption, higher oral activity, and longer .
(e.g., Albuterol): Increases selectivity. Decreases degradation, leading to increased oral activity and prolonged .
alone (e.g., Phenylephrine): Critical for selective activity with almost no activity.
No Phenolic Substitution: Retains both and activity; can act via direct or indirect (releasing) mechanisms.
Substrate Specificity for COMT:
Substrates: Catechol rings ().
Non-Substrates: Monophenols (e.g., ) and Resorcinols ().
Amine Substitution () SAR:
Must be primary () or secondary () amines. Tertiary () and quaternary amines are inactive as agonists.
Increasing the size/bulk of the substituent:
Increases receptor activity and decreases receptor activity.
Decreases inactivation by .
Increases oral bioavailability and .
An group confers selective activity and significantly decreases degradation.
Receptor Subtype Targets:
: Cardiac receptors (increase heart muscle contraction; antagonists used for hypertension).
: Tracheal/bronchial receptors (smooth muscle relaxation; agonists used for asthma).
Comparative Agonist Case Studies and Formulations
Evaluation of Phenylethylamine Agonists:
Norepinephrine (NE): Direct agonist with selectivity.
Epinephrine (E): Nonselective agonist.
Isoproterenol (ISO): Nonselective and agonist.
N-t-Butylnorepinephrine (Colterol): Selective agonist.
Safest drug choice for asthma among catecholamines due to selectivity without cardiac stimulation.
Exhibits the lowest inactivation rate by due to the bulky group.
Phenylephrine Structure and Profile:
Structure: Contains a group on the ring, a group, and an group (lacks the of Epinephrine).
Pharmacology: Selective agonist with less overall and potency than , but nearly zero activity.
Clinical Use: Available over-the-counter () as a nasal decongestant.
Metabolism: Not a substrate for , conferring a longer than Epinephrine.
Epinephrine Formulations and Oxidation:
EpiPen® (Epinephrine Injection): Auto-injectors used for emergency treatment of life-threatening severe allergic reactions () from insect bites, foods, and medications.
Oxidative Degradation: Epinephrine is easily oxidized () to a quinone analog, which rapidly degrades into Adrenochrome (causing dark coloration in expired EpiPen® units).
Dipivefrin (Prodrug Approach):
Structure: Formed by the esterification of Epinephrine's catechol hydroxyl groups with two pivalic acid molecules (forming pivaloyl diesters).
Properties of Epinephrine: Easily oxidized, less lipophilic, poor corneal absorption/penetration, highly irritating to eyes when treating glaucoma.
Properties of Dipivefrin: Non-catechol ester prodrug. Inactive until hydrolyzed. Resistant to oxidation, highly lipophilic, exhibits superior ocular absorption and corneal penetration, and causes less eye irritation than Epinephrine.
Activation: Enzymatically hydrolyzed by corneal esterases to yield active Epinephrine inside the eye.
Selective Agonists: Imidazolines and Guanidines
Selective (Imidazolines):
General SAR: Consist of an aromatic moiety connected via a methylene bridge () to an imidazoline ring.
Key Compounds:
Naphazoline (Privine): ocular/nasal decongestant.
Tetrahydrozoline (Visine): ocular decongestant.
Oxymetazoline (Afrin): nasal decongestant.
Metabolism: Not substrates for or .
Selective (Guanidines & Imidazolines):
General SAR: Consist of an aromatic moiety connected via an amino bridge () to an imidazoline ring or open guanidine group ().
Key Compounds:
Clonidine (Catapres): . Stimulates central in the brain to reduce sympathetic tone, producing an antihypertensive effect.
Guanabenz: Guanidine derivative, (completely ionized at physiological pH).
Guanfacine: Guanidine derivative ( ionized, non-ionized at pH 7.4). Stimulates central in the brain, producing an antihypertensive effect.
Short-Acting and Long-Acting Beta-2 Agonists
Short-Acting :
Albuterol (Ventolin): Top 200 asthma drug featuring a resorcinol-like pattern and an group.
Levalbuterol: Pure of albuterol.
Pirbuterol: Pyridine-containing agonist.
Metabolism: derivatives are primarily metabolized via sulfate conjugation.
Long-Acting :
Salmeterol: Contains an extended lipophilic lipophilic tail attached to the amine.
Lipophilicity Correlation: Drugs with higher lipophilicity (higher values) demonstrate prolonged tissue retention and significantly longer .
Adrenergic Receptor Antagonists (Alpha and Beta Blockers)
Quinazoline Selective :
Prazosin:
Terazosin:
Doxazosin:
Clinical Indications: Used in the treatment of hypertension and benign prostatic hyperplasia ().
Selective :
Receptor distribution: adrenoceptor subtype is predominant in prostate tissue.
Tamsulosin (Flomax): Selective blocker used for .
Alfuzosin (Uroxatral): Selective blocker used for .
General SAR of (Aryloxypropanolamines):
Scaffold structural formula: .
Nonselective :
Propranolol (Inderal): Prototypical aryloxypropanolamine nonselective .
Widely used antihypertensive. High lipophilicity enables crossing of the blood-brain barrier, resulting in side effects (e.g., dizziness, confusion, depression).
Nadolol: Nonselective .
Selective (Cardioselective):
Atenolol:
Highly hydrophilic structure results in significantly lower side effects (e.g., dizziness, confusion, depression) compared to propranolol.
Metoprolol: Selective .
Bisoprolol: Selective .